ERS International Congress 2022: highlights from the Thoracic Surgery and Lung Transplantation Assembly

The thoracic surgery and lung transplantation assembly (Assembly 8) of the European Respiratory Society (ERS) is delighted to present the highlights from the 2022 ERS International Congress that took place in a hybrid version in Barcelona, Spain. We have selected the four main sessions that discussed recent advances across a wide range of topics including the effects of coronavirus disease 2019 on thoracic surgery and the challenges regarding lung transplantation in connective tissue diseases and common variable immunodeficiency. The sessions are summarised by early career members in close collaboration with the assembly faculty. We aim to provide the reader with an update and enhanced insight into the highlights of the conference in the fields of thoracic surgery and lung transplantation. The Thoracic Surgery and Lung Transplantation Assembly (Assembly 8) of the @EuroRespSoc is delighted to present an enhanced insight into the highlights from the 2022 #ERSCongress (Spain) https://bit.ly/3HED6Jj

[1]  G. Raghu,et al.  Safety, tolerability, and efficacy of pirfenidone in patients with rheumatoid arthritis-associated interstitial lung disease: a randomised, double-blind, placebo-controlled, phase 2 study. , 2022, The Lancet. Respiratory medicine.

[2]  J. Varga,et al.  Effect of Nintedanib on Progression of Systemic Sclerosis‐Associated Interstitial Lung Disease Over 100 Weeks: Data From a Randomized Controlled Trial , 2022, ACR open rheumatology.

[3]  C. Bermudez,et al.  Managing connective tissue disease: how to select and facilitate successful transplantation , 2022, Current opinion in organ transplantation.

[4]  P. Rebora,et al.  The Role of Surgery in Patients with COVID-19-Related Thoracic Complications , 2022, Frontiers in Surgery.

[5]  P. Dieudé,et al.  A Risk Score to Detect Subclinical Rheumatoid Arthritis–Associated Interstitial Lung Disease , 2022, Arthritis & rheumatology.

[6]  H. Kehlet,et al.  Reasons for staying in hospital after video-assisted thoracoscopic surgery lobectomy , 2022, BJS open.

[7]  V. Torri,et al.  Coronavirus Disease 2019 Outcomes, Patient Vaccination Status, and Cancer-Related Delays During the Omicron Wave: A Brief Report From the TERAVOLT Analysis , 2022, JTO Clinical and Research Reports.

[8]  P. Saunders,et al.  Rituximab versus Cyclophosphamide for the Treatment of Connective Tissue Disease Associated Interstitial Lung Disease (RECITAL): A Multi-Centre Randomised Controlled Trial , 2022, C93. CLINICAL TRIALS IN CHRONIC LUNG DISEASE.

[9]  Kenji Suzuki,et al.  Segmentectomy versus lobectomy in small-sized peripheral non-small-cell lung cancer (JCOG0802/WJOG4607L): a multicentre, open-label, phase 3, randomised, controlled, non-inferiority trial , 2022, The Lancet.

[10]  H. Kehlet,et al.  Days alive and out of hospital after enhanced recovery video-assisted thoracoscopic surgery lobectomy. , 2022, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[11]  O. Lauk,et al.  Surgical management of lung cancer during the COVID-19 pandemic - a narrative review and single-centre report. , 2022, Swiss medical weekly.

[12]  J. Dunning,et al.  Video-Assisted Thoracoscopic or Open Lobectomy in Early-Stage Lung Cancer. , 2022, NEJM evidence.

[13]  S. Burns,et al.  Airway inflammation and dysbiosis in antibody deficiency despite the presence of IgG. , 2021, The Journal of allergy and clinical immunology.

[14]  F. Martinez,et al.  Long-Term Safety and Efficacy of Tocilizumab in Early Systemic Sclerosis-Interstitial Lung Disease: Open Label Extension of a Phase 3 Randomized Controlled Trial. , 2021, American journal of respiratory and critical care medicine.

[15]  W. Liang,et al.  Radical Minimally Invasive Surgery After Immuno-chemotherapy in Initially-unresectable Stage IIIB Non-small cell Lung Cancer , 2021, Annals of surgery.

[16]  N. Evans.  RE: COVID-19 Related Post-intubation Tracheal Stenosis: Early Experience with Surgical Treatment. , 2021, Annals of surgery.

[17]  M. Pirinen,et al.  Lifetime risk of rheumatoid arthritis-associated interstitial lung disease in MUC5B mutation carriers , 2021, Annals of the Rheumatic Diseases.

[18]  G. Berry,et al.  ISHLT consensus document on lung transplantation in patients with connective tissue disease: Part I: Epidemiology, assessment of extrapulmonary conditions, candidate evaluation, selection criteria, and pathology statements. , 2021, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[19]  N. Kolaitis,et al.  Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation. , 2021, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[20]  P. Dieudé,et al.  Rheumatological evaluation of patients with interstitial lung disease , 2021, Scandinavian journal of rheumatology.

[21]  N. Okiyama,et al.  Safety and efficacy of rituximab in systemic sclerosis (DESIRES): a double-blind, investigator-initiated, randomised, placebo-controlled trial. , 2021, The Lancet. Rheumatology.

[22]  K. Rabe,et al.  Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trial. , 2021, The Lancet. Respiratory medicine.

[23]  C. Cunningham-Rundles,et al.  Interstitial Lung Disease in Common Variable Immunodeficiency , 2021, Frontiers in Immunology.

[24]  A. Wells.  New insights into the treatment of CTD-ILD , 2021, Nature Reviews Rheumatology.

[25]  R. Cerfolio,et al.  Thoracic surgery outcomes for patients with Coronavirus Disease 2019 , 2021, The Journal of Thoracic and Cardiovascular Surgery.

[26]  G. Raghu,et al.  Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease treated with mycophenolate: a subgroup analysis of the SENSCIS trial. , 2021, The Lancet. Respiratory medicine.

[27]  M. Molina-Molina,et al.  Diagnostic delay of associated interstitial lung disease increases mortality in rheumatoid arthritis , 2020, Scientific Reports.

[28]  R. Porcher,et al.  Methotrexate and rheumatoid arthritis associated interstitial lung disease , 2020, European Respiratory Journal.

[29]  A. Ribechini,et al.  Evaluation of the Incidence and Potential Mechanisms of Tracheal Complications in Patients With COVID-19. , 2020, JAMA otolaryngology-- head & neck surgery.

[30]  A. Mailleux,et al.  Chaotic activation of developmental signalling pathways drives idiopathic pulmonary fibrosis , 2020, European Respiratory Review.

[31]  J. Goldin,et al.  Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial. , 2020, The Lancet. Respiratory medicine.

[32]  G. Fontanini,et al.  Laryngotracheal resection for a post-tracheotomy stenosis in a patient with coronavirus disease 2019 (COVID-19) , 2020, JTCVS Techniques.

[33]  R. Ameratunga,et al.  Defining Common Variable Immunodeficiency Disorders in 2020. , 2020, Immunology and allergy clinics of North America.

[34]  P. Dasgupta,et al.  Society of Robotic Surgery review: recommendations regarding the risk of COVID‐19 transmission during minimally invasive surgery , 2020, BJU international.

[35]  Ruchong Chen,et al.  Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China , 2020, The Lancet Oncology.

[36]  B. Griffiths,et al.  The identification and management of interstitial lung disease in systemic sclerosis: evidence-based European consensus statements. , 2020, The Lancet. Rheumatology.

[37]  S. Walsh,et al.  Nintedanib in Progressive Fibrosing Interstitial Lung Diseases. , 2019, The New England journal of medicine.

[38]  V. Lougaris,et al.  Double-blind, placebo-controlled, randomized trial on low-dose azithromycin prophylaxis in patients with primary antibody deficiencies. , 2019, The Journal of allergy and clinical immunology.

[39]  M. Neely,et al.  Factors Associated with Prolonged Survival (>15 Years) after Lung Transplantation: Analysis of the ISHLT Registry , 2019, The Journal of Heart and Lung Transplantation.

[40]  A. Aghamohammadi,et al.  Common Variable Immunodeficiency: Epidemiology, Pathogenesis, Clinical manifestations, Diagnosis, Classification and Management. , 2020, Journal of investigational allergology & clinical immunology.

[41]  P. Soler-Palacín,et al.  The Lung in Primary Immunodeficiencies: New Concepts in Infection and Inflammation , 2018, Front. Immunol..

[42]  P. Soler-Palacín,et al.  Age‐specific pediatric reference ranges for immunoglobulins and complement proteins on the Optilite™ automated turbidimetric analyzer , 2018, Journal of clinical laboratory analysis.

[43]  C. Oddis,et al.  Treatment in myositis , 2018, Nature Reviews Rheumatology.

[44]  W. Vach,et al.  Respiratory Infections and Antibiotic Usage in Common Variable Immunodeficiency , 2017, The Journal of Allergy and Clinical Immunology: In Practice.

[45]  Smita Y. Patel,et al.  British Lung Foundation/United Kingdom Primary Immunodeficiency Network Consensus Statement on the Definition, Diagnosis, and Management of Granulomatous-Lymphocytic Interstitial Lung Disease in Common Variable Immunodeficiency Disorders. , 2017, The journal of allergy and clinical immunology. In practice.

[46]  P. Froguel,et al.  Shared genetic predisposition in rheumatoid arthritis-interstitial lung disease and familial pulmonary fibrosis , 2017, European Respiratory Journal.

[47]  E. Trallero-Araguás,et al.  Clinical manifestations and long-term outcome of anti-Jo1 antisynthetase patients in a large cohort of Spanish patients from the GEAS-IIM group. , 2016, Seminars in arthritis and rheumatism.

[48]  B. Lambrecht,et al.  Genes associated with common variable immunodeficiency: one diagnosis to rule them all? , 2016, Journal of Medical Genetics.

[49]  E. Gelfand,et al.  Common Variable Immunodeficiency: Diagnosis, Management, and Treatment. , 2015, Immunology and allergy clinics of North America.

[50]  S. Spector,et al.  Practice parameter for the diagnosis and management of primary immunodeficiency. , 2015, The Journal of allergy and clinical immunology.

[51]  J. Verbsky,et al.  Sarcoidosis and Common Variable Immunodeficiency: Similarities and Differences , 2014, Seminars in Respiratory and Critical Care Medicine.

[52]  G. Kayser,et al.  Common variable immunodeficiency-associated granulomatous and interstitial lung disease , 2013, Current opinion in pulmonary medicine.

[53]  R. Sharp,et al.  Genetics patients' perspectives on clinical genomic testing. , 2013, Personalized medicine.

[54]  T. Fujita,et al.  RNA helicase encoded by melanoma differentiation-associated gene 5 is a major autoantigen in patients with clinically amyopathic dermatomyositis: Association with rapidly progressive interstitial lung disease. , 2009, Arthritis and rheumatism.

[55]  N. McHugh,et al.  Myositis-specific autoantibodies: their clinical and pathogenic significance in disease expression. , 2009, Rheumatology.

[56]  J. North,et al.  Anti-synthetase syndrome: a new autoantibody to phenylalanyl transfer RNA synthetase (anti-Zo) associated with polymyositis and interstitial pneumonia. , 2007, Rheumatology.

[57]  N. Milman,et al.  Common variable immune deficiency and lung transplantation , 2007, Scandinavian journal of infectious diseases.

[58]  L. Sharples,et al.  The outcomes of lung transplantation in patients with bronchiectasis and antibody deficiency. , 2005, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[59]  C. Angeletti,et al.  Acute major airway injuries: clinical features and management. , 2001, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.